0000950170-24-026583.txt : 20240305
0000950170-24-026583.hdr.sgml : 20240305
20240305193823
ACCESSION NUMBER: 0000950170-24-026583
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sabens Andrea
CENTRAL INDEX KEY: 0001876279
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36569
FILM NUMBER: 24723657
MAIL ADDRESS:
STREET 1: C/O LANTHEUS HOLDINGS, INC.
STREET 2: 331 TREBLE COVE ROAD
CITY: NORTH BILLERICA
STATE: MA
ZIP: 01862
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lantheus Holdings, Inc.
CENTRAL INDEX KEY: 0001521036
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 352318913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 331 TREBLE COVE ROAD
CITY: NORTH BILLERICA
STATE: MA
ZIP: 01862
BUSINESS PHONE: 978 671-8001
MAIL ADDRESS:
STREET 1: 331 TREBLE COVE ROAD
CITY: NORTH BILLERICA
STATE: MA
ZIP: 01862
FORMER COMPANY:
FORMER CONFORMED NAME: Lantheus MI Holdings, Inc.
DATE OF NAME CHANGE: 20110517
4
1
ownership.xml
4
X0508
4
2024-03-01
0001521036
Lantheus Holdings, Inc.
LNTH
0001876279
Sabens Andrea
C/O LANTHEUS HOLDINGS, INC.
201 BURLINGTON ROAD, SOUTH BLDG
BEDFORD
MA
01730
false
true
false
false
Chief Accounting Officer
false
Common Stock
2024-03-01
4
A
false
5685
0.00
A
64088
D
Common Stock
2024-03-04
4
A
false
5817
0.00
A
69905
D
Stock Option (right to buy)
64.64
2024-03-01
4
A
false
3368
0.00
A
2034-03-01
Common Stock
3368
3368
D
Consists of 1,895 restricted stock units that vest in equal installments over a three-year period and 3,790 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
The transaction reported in this Form 4 reflects additional shares of common stock issued by the Company to the reporting person upon the vesting of relative Total Shareholder Return PSUs that were previously granted and included in the Form 3 filed upon the reporting person becoming a Section 16 officer. The number of shares reported in the Form 3 reflected 100% of the target number of shares underlying the PSUs. The number of shares that actually vested under the PSUs equaled 200% of the target number of shares. Accordingly, the number of shares reported in this Form 4 reflects the difference between the number of shares that actually vested under the PSUs and the target number of shares originally included in the Form 3.
The option vests in three equal annual installments beginning on March 1, 2025.
/s/ Eric M. Green, attorney-in-fact
2024-03-05